 |
Case Report
Mixed diffuse angiomatosis/lymphangiomatosis of the breast in SLE patient: An unusual case report and literature review
1 Resident, Department of Pathology, Imam Abdulrahman Bin Faisal University, King Fahad University Hospital, Al Khobar, Eastern Province, Saudi Arabia
2 Associate Professor, Department of Pathology, Imam Abdulrahman Bin Faisal University, King Fahad University Hospital, Al Khobar, Eastern Province, Saudi Arabia
3 Professor, Department of Surgery, Imam Abdulrahman Bin Faisal University, King Fahad University Hospital, Al Khobar, Eastern Province, Saudi Arabia
4 Assistant Professor, Department of Radiology, Imam Abdulrahman Bin Faisal University, King Fahad University Hospital, Al Khobar, Eastern Province, Saudi Arabia
5 Assistant Professor, Department of Dermatology, Imam Abdulrahman Bin Faisal University, King Fahad University Hospital, Al Khobar, Eastern Province, Saudi Arabia
Address correspondence to:
Tarek El Sharkawy
King Fahd Hospital, Accommodation (Site1), Alaqrabiyah 2916, Unit 134, Khobar 34446, Eastern Province,
Saudi Arabia
Message to Corresponding Author
Article ID: 100035Z11ZA2020
Access full text article on other devices
Access PDF of article on other devices
How to cite this article
Al-Turaifi Z, El Sharkawy T, Abdel-Hadi M, Al-Muhana A, Al Brieki S. Mixed diffuse angiomatosis/lymphangiomatosis of the breast in SLE patient: An unusual case report and literature review. J Case Rep Images Pathol 2020;6:100035Z11ZA2020.ABSTRACT
Introduction: Angiomatosis/lymphangiomatosis is a rare, reactive angioproliferative lesion in the skin and is considered to be a subtype in the group of cutaneous reactive angiomatoses. However, few cases of diffuse dermal angiomatosis of the breast (DDAB) have been reported in the literature.
Case Report: In this case report, we present a patient known to have systemic lupus erythematosus (SLE) with mixed diffuse angiomatosis/lymphangiomatosis of both breasts mimicking inflammatory carcinoma. We describe the clinical and histopathologic characteristics, pathogenetic mechanisms, and predisposing risk factors of this rare skin disorder and discuss treatment options.
Conclusion: Currently, there is no agreement on the best therapeutic approach. Isotretinoin and other medical therapies have been used with limited success. Laser therapy and breast reduction appears to be a reliable treatment option for DDAB and might provide definitive treatment.
Keywords: Angiomatosis, Breast, Lymphangiomatosis, SLE
SUPPORTING INFORMATION
Author Contributions
Zahra Al-Turaifi - Substantial contributions to conception and design, Acquisition of data, Interpretation of data, Final approval of the version to be published
Tarek El Sharkawy - Substantial contributions to conception and design, Analysis of data, Interpretation of data, Revising it critically for important intellectual content, Final approval of the version to be published
Maha Abdel-Hadi - Substantial contributions to conception and design, Revising it critically for important intellectual content, Final approval of the version to be published
Afnan Al-Muhana - Acquisition of data, Analysis of data, Revising it critically for important intellectual content, Final approval of the version to be published
Sara Al Brieki - Acquisition of data, Analysis of data, Revising it critically for important intellectual content, Final approval of the version to be published
Guarantor of SubmissionThe corresponding author is the guarantor of submission.
Source of SupportNone
Consent StatementWritten informed consent was obtained from the patient for publication of this article.
Data AvailabilityAll relevant data are within the paper and its Supporting Information files.
Conflict of InterestAuthors declare no conflict of interest.
Copyright© 2020 Zahra Al-Turaifi et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.
